Last €3.93 EUR
Change Today +0.008 / 0.20%
Volume 0.0
RMEA On Other Exchanges
Symbol
Exchange
New York
OTC US
Frankfurt
Frankfurt
As of 11:12 AM 09/19/14 All times are local (Market data is delayed by at least 15 minutes).

resmed inc-cdi (RMEA) Snapshot

Open
€3.93
Previous Close
€3.93
Day High
€3.93
Day Low
€3.93
52 Week High
09/12/14 - €4.15
52 Week Low
03/25/14 - €3.05
Market Cap
5.5B
Average Volume 10 Days
203.0
EPS TTM
--
Shares Outstanding
1.4B
EX-Date
08/19/14
P/E TM
--
Dividend
€0.11
Dividend Yield
1.93%
Current Stock Chart for RESMED INC-CDI (RMEA)

resmed inc-cdi (RMEA) Related Businessweek News

No Related Businessweek News Found

resmed inc-cdi (RMEA) Details

ResMed Inc. develops, manufactures, distributes, and markets medical equipment for the diagnosis, treatment, and management of respiratory disorders, with a focus on sleep-disordered breathing. Its products portfolio includes airflow generators, diagnostic products, mask systems, motors, and headgear, as well as other accessories, such as cold passover humidifiers, carry bags, and breathing circuits; and humidifiers comprising H5i and H4i, which connect with the continuous and variable positive airway pressure, and AutoSet flow generators to humidify and heat the air delivered to the patient to prevent the drying of nasal passages. The company also offers data communications and control products, including EasyCare, ResLink, ResControl, ResControl II, TxControl, ResScan, and ResTraxx modules that facilitate the transfer of data and other information to and from the flow generators. ResMed Inc. markets its products to sleep clinics, home healthcare dealers, and third-party payers. The company sells its products through a network of distributors and direct sales force in approximately 100 countries worldwide. It has a collaboration agreement with Qualcomm Life, Inc. to develop connected health solutions based on 2net and HealthyCircles platforms. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.

4,100 Employees
Last Reported Date: 08/8/14
Founded in 1989

resmed inc-cdi (RMEA) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $511.2K
President and Chief Operating Officer
Total Annual Compensation: $588.8K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $505.3K
President of SDB Strategic Business Unit
Total Annual Compensation: $385.0K
President of Americas
Total Annual Compensation: $379.8K
Compensation as of Fiscal Year 2013.

resmed inc-cdi (RMEA) Key Developments

ResMed and Fairview Health Services Introduce Integration of Sleep and Respiratory Therapy Data into EHR System

ResMed announced that its AirView compliance management platform (previously EasyCare Online) is now securely connected to Fairview Health Services' Epic EHR system, enabling up to date delivery of sleep apnea patient data for use by Fairview's medical staff. Launched in June 2014, the integration of this data supports streamlined workflow, reduced cost, improved quality and responsiveness of therapy, and automated access to data for analytical and clinical outcome decision support. Sleep apnea occurs when an individual stops breathing for a period of at least 10 seconds while asleep, 5 times or more per hour. The condition affects more than 3 in 10 men and nearly 1 in 5 women(i), and is associated with comorbidities including heart failure, diabetes, and hypertension. The most commonly utilized treatment for sleep apnea is positive airway pressure (PAP) therapy, which keeps the airway open to prevent apnea events from occurring. Research has shown that consistent use of PAP therapy is associated with improved health outcomes. Data generated by PAP devices, such as the ResMed S9 series and AirSense(TM) 10 series, enables medical professionals to remotely monitor patient therapy compliance to take appropriate action based on specific outcomes. With ResMed's AirView connection to Fairview's Epic EHR, clinicians now have access to patient PAP therapy data within their EHR system, eliminating the need to log in to multiple patient management systems to view patient outcomes. Key features enabled with this solution include: Boarding of sleep therapy patients from the EHR into the ResMed AirView patient management system. Daily updating of PAP therapy effectiveness data from the patient's home directly into the EHR via AirView. Sleep health therapy management workflow and tracking tools embedded in the EHR, displaying key patient PAP metrics for various time intervals, customized to meet the needs of Fairview clinicians. Creation of a secure patient data warehouse to support advanced analytics such as the impact of sleep apnea on comorbid conditions.

ResMed Introduces New Positive-Airway Pressure Device Platform

ResMed introduced its new AirSense 10 positive-airway pressure, or PAP, device platform. The AirSense 10 series PAP devices are the cornerstones of the ResMed Air Solutions connected care platform, an ecosystem of hardware and software solutions that can significantly streamline the patient compliance monitoring and management process while improving overall patient outcomes and engagement. The AirSense 10 series works with ResMed's AirView patient monitoring software. Formerly called EasyCare Online, AirView seamlessly works with AirSense 10 devices to track, analyze and report a patient's usage and compliance as well as make the device's status visible to healthcare providers. The AirSense 10 series devices are available now in the US and Australia and include four new devices: AirSense 10 CPAP, AirSense 10 Elite, AirSense 10 AutoSet and AirSense 10 AutoSet for Her. AirSense 10 CPAP has all of the advanced features that are standard with AirSense 10 series devices. AirSense 10 Elite is a step-up CPAP device that includes detection of central sleep apneas and Cheyne-Stokes respiration. The AirSense 10 AutoSet devices continually monitor breathing, adapting breath by breath to always deliver the lowest therapeutic pressure, improving comfort and sleep. AirSense 10 AutoSet for Her is the first and only FDA-cleared device that provides specialized sleep apnea therapy for women based upon specific female breathing patterns. It uses a clinically proven algorithm designed to treat mild to moderate sleep apnea in women. Key AirSense 10 series features that break new ground in therapy for sleep-disordered breathing include: Connected care; Remote device settings changes and troubleshooting; Integrated HumidAir heated humidification; AutoRamp; and Simple, elegant user-friendly controls for patient confidence. Every AirSense 10 device is enabled for data on demand with wireless communications out of the box - no module, SD card, or pairing to a smart phone is necessary. That means that each device is always on, tracking patient therapy data that is available to providers just one hour after the device's last use, facilitating more timely patient interventions. The power of communications means that healthcare providers can troubleshoot and change settings without the cost of sending staff to check on a device or manually change the therapy settings. And using ResMed's AirView web-based software, providers can view the device's status at a glance and determine whether the device requires service or if instead an issue may be resolved remotely with a click of a mouse. All ResMed AirSense devices have integrated HumidAir heated humidifiers that afford a more compact bedside footprint. In addition to more comfort and fewer parts to manage for the patient, the integrated humidifier also means less inventory to track for HMEs. AutoRamp feature uses sleep onset detection to keep pressure low before delivering full therapy pressure as soon as the patient falls asleep to enhance therapy compliance. ResMed has redesigned and significantly streamlined its user interface to enable patients to operate their devices with more confidence. AirSense 10 series devices also have an angled LCD screen for easy bedside viewing, and an ambient light sensor to adjust to the brightness of the room, so the screen's backlight won't disturb the user or the bed partner during the night.

ResMed Inc. Introduces Astral 100 and 150 Devices Now Available in the U.S

ResMed Inc. has introduced the Astral 100 and Astral 150 devices in the United States. The Astral platform is ResMed's new generation of portable, lightweight, and user-friendly life support ventilators. ResMed's new Astral life support ventilators offer unparalleled mobility and ease of use for patients suffering from neuromuscular disease, chronic obstructive pulmonary disease (COPD), and other adult and childhood respiratory disorders. The U.S. launch comes on the heels of Astral's successful introduction to European and select Asia-Pacific markets earlier this year. Astral 100 Life Support Ventilator: Astral 100 is the powerful, entry-level model in the new generation of ResMed's portable, lightweight and user-friendly life support ventilators. Key features of the Astral 100 life support ventilator include: Exceptional battery-life and portability: up to 24 hours. Streamlined setup and operation. Excellent leak compensation. The ability to use non-invasively or invasively with a mask, mouthpiece, or tracheostomy. A single valve circuit system with one integrated QuickConnec tube and leak circuit options. Intuitive, easy-to-read touch screen display with real-time pressure and flow data for a comprehensive picture of a patient's condition. Astral 150 Life Support Ventilator: The Astral 150 life support ventilator is an even more versatile solution that builds on the features of the Astral 100 life support ventilator by adding: A double-circuit system to more accurately measure a patient's exhaled breath in real time. This makes it an ideal choice for a wider range of patients, including children who have more sensitive respiratory needs. Manual breath and sigh features to mimic natural breathing patterns, and the option to configure up to four ventilation programs that can be set to meet a patient's changing daily requirements. The ability to monitor the percentage of enriched oxygen used by a patient.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RMEA:GR €3.93 EUR +0.008

RMEA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Hologic Inc $24.14 USD -0.43
IDEXX Laboratories Inc $116.78 USD -3.01
Mettler-Toledo International Inc $265.36 USD -2.68
Teleflex Inc $108.35 USD -0.96
Cooper Cos Inc/The $159.15 USD +2.14
View Industry Companies
 

Industry Analysis

RMEA

Industry Average

Valuation RMEA Industry Range
Price/Earnings 21.4x
Price/Sales 4.6x
Price/Book 4.1x
Price/Cash Flow 20.3x
TEV/Sales 3.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact RESMED INC-CDI, please visit www.resmed.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.